| Title: |
1077TiP TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study |
| Authors: |
Singh, H.; Diamond, J.R.; Henry, J.T.; Olszanski, A.J.; Rasco, D.; Patel, S.P.; Gregory, R.; Appleman, V.A.; Gibbs, J.P.; Zhang, W.; Wang, C.I.; Parent, A.A.; Chung, V. |
| Contributors: |
Takeda Pharmaceutical Company |
| Source: |
Annals of Oncology ; volume 34, page S648-S649 ; ISSN 0923-7534 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2023 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/j.annonc.2023.09.2974 |
| Availability: |
http://dx.doi.org/10.1016/j.annonc.2023.09.2974; https://api.elsevier.com/content/article/PII:S0923753423038115?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0923753423038115?httpAccept=text/plain |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/legal/tdmrep-license ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| Accession Number: |
edsbas.23A40335 |
| Database: |
BASE |